VERSATIS lidocaine (lignocaine) 5% w/w dermal patch Australien - Englisch - Department of Health (Therapeutic Goods Administration)

versatis lidocaine (lignocaine) 5% w/w dermal patch

seqirus pty ltd - lidocaine, quantity: 0.7 g - patch, dermal - excipient ingredients: urea; propylene glycol; polyvinyl alcohol; heavy kaolin; gelatin; methyl hydroxybenzoate; aluminium glycinate; sorbitol solution (70 per cent) (crystallising); sodium polyacrylate; polyacrylic acid; carmellose sodium; tartaric acid; glycerol; propyl hydroxybenzoate; purified water; disodium edetate - for the treatment of symptomatic relief of neuropathic pain associated with previous herpes zoster infection (post-herpetic neuralgia, phn)

TRAMAL ORAL DROPS tramadol hydrochloride 100mg/mL oral liquid bottle Australien - Englisch - Department of Health (Therapeutic Goods Administration)

tramal oral drops tramadol hydrochloride 100mg/ml oral liquid bottle

seqirus pty ltd - tramadol hydrochloride, quantity: 100 mg/ml - oral liquid, solution - excipient ingredients: sucrose; propylene glycol; sodium cyclamate; saccharin sodium; purified water; glycerol; ethoxylated hydrogenated castor oil; mint oil dementholised; potassium sorbate; flavour - tramal oral drops are indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

TRAMAL SR tramadol hydrochloride 200mg modified release tablet blister pack Australien - Englisch - Department of Health (Therapeutic Goods Administration)

tramal sr tramadol hydrochloride 200mg modified release tablet blister pack

seqirus pty ltd - tramadol hydrochloride, quantity: 200 mg - tablet, modified release - excipient ingredients: magnesium stearate; macrogol 6000; titanium dioxide; hypromellose; colloidal anhydrous silica; microcrystalline cellulose; lactose monohydrate; propylene glycol; iron oxide red; iron oxide black; purified talc; quinoline yellow aluminium lake; iron oxide yellow - tramal sr is indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long term treatment. tramal sr is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. tramal sr is not indicated as an as-needed (prn) analgesia.

TRAMAL SR tramadol hydrochloride 150mg modified release tablet blister pack Australien - Englisch - Department of Health (Therapeutic Goods Administration)

tramal sr tramadol hydrochloride 150mg modified release tablet blister pack

seqirus pty ltd - tramadol hydrochloride, quantity: 150 mg - tablet, modified release - excipient ingredients: hypromellose; quinoline yellow aluminium lake; microcrystalline cellulose; purified talc; lactose monohydrate; magnesium stearate; propylene glycol; iron oxide red; colloidal anhydrous silica; macrogol 6000; titanium dioxide - tramal sr is indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long term treatment. tramal sr is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. tramal sr is not indicated as an as-needed (prn) analgesia.

TRAMAL SR tramadol hydrochloride 100mg modified release tablet blister pack Australien - Englisch - Department of Health (Therapeutic Goods Administration)

tramal sr tramadol hydrochloride 100mg modified release tablet blister pack

seqirus pty ltd - tramadol hydrochloride, quantity: 100 mg - tablet, modified release - excipient ingredients: hypromellose; lactose monohydrate; colloidal anhydrous silica; macrogol 6000; magnesium stearate; purified talc; titanium dioxide; microcrystalline cellulose; propylene glycol - tramal sr is indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long term treatment. tramal sr is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. tramal sr is not indicated as an as-needed (prn) analgesia.

TRAMAL tramadol hydrochloride 50mg capsule blister pack Australien - Englisch - Department of Health (Therapeutic Goods Administration)

tramal tramadol hydrochloride 50mg capsule blister pack

seqirus pty ltd - tramadol hydrochloride, quantity: 50 mg - capsule, hard - excipient ingredients: colloidal anhydrous silica; magnesium stearate; microcrystalline cellulose; sodium starch glycollate; gelatin; titanium dioxide; iron oxide yellow; sodium lauryl sulfate - tramal capsules are indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

TRAMAL tramadol hydrochloride 100mg/2mL injection ampoule Australien - Englisch - Department of Health (Therapeutic Goods Administration)

tramal tramadol hydrochloride 100mg/2ml injection ampoule

seqirus pty ltd - tramadol hydrochloride, quantity: 50 mg/ml - injection, solution - excipient ingredients: water for injections; sodium acetate - tramal solution for injection is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

TRAMAL tramadol hydrochloride 50mg/1mL injection ampoule Australien - Englisch - Department of Health (Therapeutic Goods Administration)

tramal tramadol hydrochloride 50mg/1ml injection ampoule

seqirus pty ltd - tramadol hydrochloride, quantity: 50 mg/ml - injection, solution - excipient ingredients: sodium acetate; water for injections - tramal solution for injection is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

ACARIZAX (American house dust mite extract and European house dust mite extract) SUBLINGUAL TABLET Australien - Englisch - Department of Health (Therapeutic Goods Administration)

acarizax (american house dust mite extract and european house dust mite extract) sublingual tablet

seqirus pty ltd - european house dust mite extract, quantity: 6 sq-hdm; american house dust mite extract, quantity: 6 sq-hdm - tablet - excipient ingredients: gelatin; sodium hydroxide; purified water; mannitol - allergic rhinitis acarizax is indicated for the treatment of house dust mite (hdm) allergic rhinitis not well controlled despite use of symptom relieving medication in adults and adolescents (? 12 years). allergic asthma acarizax is indicated for the treatment of hdm allergic asthma not well controlled by inhaled corticosteroids and associated with hdm allergic rhinitis in adults. patients? asthma status should be carefully evaluated before the initiation of treatment.

FLUAD inactivated influenza vaccine (surface antigen) suspension for injection, adjuvanted, 0.5 mL syringe 2019 Australien - Englisch - Department of Health (Therapeutic Goods Administration)

fluad inactivated influenza vaccine (surface antigen) suspension for injection, adjuvanted, 0.5 ml syringe 2019

seqirus pty ltd - influenza virus haemagglutinin, quantity: 30 microgram/ml - injection, suspension - excipient ingredients: sodium chloride; potassium chloride; monobasic potassium phosphate; dibasic sodium phosphate dihydrate; magnesium chloride hexahydrate; calcium chloride dihydrate; squalene; polysorbate 80; sorbitan trioleate; sodium citrate dihydrate; citric acid monohydrate; water for injections - active immunisation against influenza in the elderly (65 years of age and older), especially for those with an increased risk of associated complications (i.e. patients affected by underlying chronic diseases including diabetes, cardiovascular and respiratory diseases).